Latest Therapies under investigation for multiple sclerosis Stories
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis.
According to data published in the Lancet Neurology, daclizumab combined with interferon beta reduced MS lesion formation 72 percent more than interferon beta alone.
ROCKLAND, Mass., Jan.
Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).
ROCKLAND, Mass., Sept. 30 /PRNewswire/ -- EMD Serono, Inc.
WALTHAM, Mass., Sept.
According to data supplied by the German Multiple Sclerosis Societyâ€™s national MS register (DMSG - Deutsche Multiple Sklerose Gesellschaft), up to 10% of German MS patients have been treated with mitoxantrone in the past few years.
CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS).
Twenty-seven percent of multiple sclerosis patients are declining to fill their prescriptions, U.S.
SEATTLE, April 29 /PRNewswire/ -- New analyses of data from the 16-Year Long-term Follow-up study with Betaseron(R) (interferon beta-1b), sponsored by Bayer HealthCare Pharmaceuticals, were presented at the American Academy of Neurology's (AAN) 61st Annual Meeting.